Second Generation Antidysrhythmic Agents

Baker, 1982, Effects of propafenone on left ventricular function (abstr), Circulation, 67, 11 Campbell, 1987, Mexiletine, N Engl J Med, 316, 29, 10.1056/NEJM198701013160106 Chase, 1987, Encainide hydrochloride and flecainide acetate: Two class IC antiarrhythmic agents, Clin Pharm, 6, 839 Chesnie, 1983, Encainide for refractory ventricular tachyarrhythmias, Am J Cardiol, 52, 495, 10.1016/0002-9149(83)90014-0 Conrad, 1984, Metabolism of flecainide, Am J Cardiol, 53, 41b, 10.1016/0002-9149(84)90501-0 Duff, 1981, Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide, Am J Cardiol, 48, 1133, 10.1016/0002-9149(81)90331-3 Duff, 1983, Mexiletine in the treatment of resistant ventricular arrhythmias: Enhancement of efficacy and reduction of dose-related side effects by combination with quinidine, Circulation, 67, 1124, 10.1161/01.CIR.67.5.1124 Fenster, 1986, Pharmacology and clinical use of mexiletine, Pharmacotherapy, 6, 1, 10.1002/j.1875-9114.1986.tb03442.x Harris, 1983, Side effects and possible contraindications of amiodarone use, Am Heart J, 106, 916, 10.1016/0002-8703(83)90016-9 Harron, 1987, Propafenone: A re view of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias, Drugs, 34, 617, 10.2165/00003495-198734060-00001 Holmes, 1983, Tocainide: A review of its pharmacological properties and therapeutic efficacy, Drugs, 26, 93, 10.2165/00003495-198326020-00001 Horowitz, 1987, Second generation antiarrhythmic agents: Have we reached antiar-hythmic nirvana?, J Am Coll Cardiol, 9, 459, 10.1016/S0735-1097(87)80405-9 Kates, 1982, Metabolite ac cumulation during long-term oral encainide administration, Clin Pharmacol Ther, 31, 427, 10.1038/clpt.1982.55 Mason, 1986, Basic and clinical cardiac electrophysiology of encainide, Am J Cardiol, 58, 18c, 10.1016/0002-9149(86)90099-8 Morganroth, 1987, Differential utility of antiarrhythmic agents, Cardiol, 74, 57, 10.1159/000174287 Nestico, 1988, New an tiarrhythmic drugs, Drugs, 35, 286, 10.2165/00003495-198835030-00005 Podrid, 1981, Mexiletine for ventricular arrhythmias, Am J Cardiol, 47, 895, 10.1016/0002-9149(81)90191-0 Podrid, 1985, Antiarrhythmic drug therapy: Benefits and hazards, Part 1, Chest, 88, 452, 10.1378/chest.88.3.452 Podrid, 1985, Antiarrhythmic drug therapy: Benefits and hazards, Part 2, Chest, 88, 618, 10.1378/chest.88.4.618 Prystowsky, 1985, Amio darone treatment in patients with ventricular arrhythmias, Drugs, 29, 47, 10.2165/00003495-198500293-00007 Rinkenberger, 1988, Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia, Am J Cardiol, 62, 44D, 10.1016/0002-9149(88)90507-3 Roden, 1986, Flecainide, N Engl J Med, 315, 36, 10.1056/NEJM198607033150106 Roden, 1986, Tocainide, N Engl J Med, 315, 41, 10.1056/NEJM198607033150107 Siddoway, 1983, Amiodarone dosing: A proposal based on its pharmacokinetics, Am Heart J, 106, 916, 10.1016/0002-8703(83)90021-2 Siddoway, 1987, Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences, Circulation, 75, 785, 10.1161/01.CIR.75.4.785 Smith, 1987, The clinical pharmacology of propafenone, J Electrophys, 1, 517, 10.1111/j.1540-8167.1987.tb01443.x Upward, 1983, The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction, Eur J Clin Pharmacol, 25, 589, 10.1007/BF00542344 Wehmeyer, 1986, Encainide: A new an tiarrhythmic agent, Drug Intel Clin Pharm, 20, 9, 10.1177/106002808602000101 Zipes, 1984, Amiodarone: Electrophysiologic actions, pharmacokinetics, and clinical effects, J Am Coll Cardiol, 3, 1059, 10.1016/S0735-1097(84)80367-8